Hypertension is a major cardiovascular risk factor but most patients remain asymptomatic for
many years. Successful therapy not only needs to be effective, it also needs to be well …

Background Nebivolol is a novel, β1‐adrenergic receptor blocker with vasodilatory
properties mediated through activation of the L‐arginine/nitric oxide pathway. Hypothesis …

Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

Background Nebivolol represents a therapeutic class of beta blockers with high beta 1
selectivity and modulatory effect on vascular reactions by releasing nitric oxide (NO) from …

This placebo-controlled multifactorial design trial assessed the antihypertensive efficacy of
nebivolol, a novel cardioselective β1-blocker with vasodilating properties, and …

Abstract Introduction: Hypertension,“The silent killer” is a multifactorial disorder which is
asymptomatic and if left untreated leads to lethal complications. Nebivolol is a third …

Objectives Some β-blockers are less effective in reducing central blood pressure than other
antihypertensive drugs, which may explain the higher rate of events in subjects randomized …

Objective: Nebivolol is a selective β 1-adrenergic receptor blocker possessing an ancillary
vasodilating effect. The objective of the present study was to study the haemodynamic and …

Background: Effective blood pressure (BP)-lowering therapy is regarded as the most
important intervention in diabetes mellitus. Nebivolol is commonly used for the treatment of …

The efficacy and safety of 2 cardioselective β-blockers, metoprolol 100mg twice daily and
nebivolol 5mg once daily, were compared in 155 patients with mild to moderate …